---
schema_version: "secwatch.filing_event.v1"
accession: "0001129928-26-000045"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-07-20T13:03:03+00:00"
generated_at: "2026-07-20T13:04:04.902498+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oncolytics Biotech receives FDA Fast Track for pelareorep in second-line anal cancer

## Summary
- FDA granted Fast Track for pelareorep + checkpoint inhibitor in inoperable/metastatic squamous cell anal carcinoma after prior therapy.
- GOBLET study showed ORR ~30% (vs historical ~15%), median DOR ~15.5 months, 12-month OS 82% (vs 45.7%).
- No FDA-approved therapies exist for patients progressing after first-line standard of care; estimated US market ~$1B annually.
- Third Fast Track designation in GI cancers (after KRAS-mCRC Feb 2026 and pancreatic cancer 2022).
- Company believes clear regulatory framework in place for pivotal study following April 2026 FDA meeting.

## SEC filing metadata
- accession: 0001129928-26-000045
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-07-20T13:03:03+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000045/0001129928-26-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000045/oncy-20260720.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001129928-26-000045
- JSON: https://secwatch.observer/filing/0001129928-26-000045.json
- Plain text: https://secwatch.observer/filing/0001129928-26-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.